Vimta Labs Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 3/6
Vimta Labs verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 27.2%, während die Gewinne der Branche Life Sciences jährlich um gewachsen und zwar um 25.2%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 13.7%. Die Eigenkapitalrendite von Vimta Labs beträgt 14.4% und die Nettomargen betragen 14.6%.
Wichtige Informationen
27.2%
Wachstumsrate der Gewinne
27.1%
EPS-Wachstumsrate
| Life Sciences Wachstum der Industrie | 11.2% |
| Wachstumsrate der Einnahmen | 13.7% |
| Eigenkapitalrendite | 14.4% |
| Netto-Marge | 14.6% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Subdued Growth No Barrier To Vimta Labs Limited (NSE:VIMTALABS) With Shares Advancing 28%
Nov 09
There's Reason For Concern Over Vimta Labs Limited's (NSE:VIMTALABS) Massive 31% Price Jump
Sep 06It Looks Like Shareholders Would Probably Approve Vimta Labs Limited's (NSE:VIMTALABS) CEO Compensation Package
Jul 12Vimta Labs (NSE:VIMTALABS) Seems To Use Debt Quite Sensibly
Jun 12Market Might Still Lack Some Conviction On Vimta Labs Limited (NSE:VIMTALABS) Even After 26% Share Price Boost
Apr 26It's A Story Of Risk Vs Reward With Vimta Labs Limited (NSE:VIMTALABS)
Jan 06If EPS Growth Is Important To You, Vimta Labs (NSE:VIMTALABS) Presents An Opportunity
Jul 14Vimta Labs (NSE:VIMTALABS) Has Announced A Dividend Of ₹2.00
Jun 03Vimta Labs' (NSE:VIMTALABS) Dividend Will Be ₹2.00
May 06A Look At The Intrinsic Value Of Vimta Labs Limited (NSE:VIMTALABS)
Dec 07Here's Why We Think Vimta Labs (NSE:VIMTALABS) Might Deserve Your Attention Today
Nov 06Vimta Labs (NSE:VIMTALABS) Is Due To Pay A Dividend Of ₹2.00
Jun 02Does Vimta Labs (NSE:VIMTALABS) Deserve A Spot On Your Watchlist?
Dec 06Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly
Oct 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Vimta Labs Limited's (NSE:VIMTALABS) CEO For Now
Jun 29Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?
Jun 19Here's Why Vimta Labs (NSE:VIMTALABS) Can Manage Its Debt Responsibly
Mar 09Vimta Labs Limited's (NSE:VIMTALABS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 20Did You Miss Vimta Labs' (NSE:VIMTALABS) 87% Share Price Gain?
Dec 30Does Vimta Labs (NSE:VIMTALABS) Have A Healthy Balance Sheet?
Dec 09
Here's What We Learned About The CEO Pay At Vimta Labs Limited (NSE:VIMTALABS)
Nov 17Vimta Labs Limited's (NSE:VIMTALABS) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Oct 21Aufschlüsselung der Einnahmen und Ausgaben
Wie Vimta Labs Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 3,376 | 493 | 1,075 | 0 |
| 30 Jun 24 | 3,176 | 411 | 1,056 | 0 |
| 31 Mar 24 | 3,193 | 410 | 1,058 | 0 |
| 31 Dec 23 | 3,212 | 413 | 1,044 | 0 |
| 30 Sep 23 | 3,169 | 415 | 1,019 | 0 |
| 30 Jun 23 | 3,234 | 483 | 999 | 0 |
| 31 Mar 23 | 3,190 | 482 | 980 | 0 |
| 31 Dec 22 | 3,109 | 473 | 975 | 0 |
| 30 Sep 22 | 3,009 | 488 | 937 | 0 |
| 30 Jun 22 | 2,965 | 453 | 879 | 0 |
| 31 Mar 22 | 2,787 | 413 | 834 | 0 |
| 31 Dec 21 | 2,644 | 372 | 771 | 0 |
| 30 Sep 21 | 2,557 | 336 | 738 | 0 |
| 30 Jun 21 | 2,396 | 314 | 718 | 0 |
| 31 Mar 21 | 2,110 | 214 | 665 | 0 |
| 31 Dec 20 | 1,945 | 137 | 637 | 0 |
| 30 Sep 20 | 1,873 | 104 | 635 | 0 |
| 30 Jun 20 | 1,694 | 37 | 594 | 0 |
| 31 Mar 20 | 1,811 | 68 | 653 | 0 |
| 31 Dec 19 | 1,914 | 136 | 684 | 0 |
| 30 Sep 19 | 1,906 | 140 | 673 | 0 |
| 30 Jun 19 | 2,025 | 200 | 671 | 0 |
| 31 Mar 19 | 2,130 | 253 | 665 | 0 |
| 31 Dec 18 | 2,126 | 236 | 666 | 0 |
| 30 Sep 18 | 2,071 | 245 | 646 | 0 |
| 30 Jun 18 | 1,970 | 218 | 621 | 0 |
| 31 Mar 18 | 1,836 | 164 | 595 | 0 |
| 31 Dec 17 | 1,693 | 134 | 562 | 0 |
| 30 Sep 17 | 1,602 | 104 | 548 | 0 |
| 30 Jun 17 | 1,552 | 83 | 534 | 0 |
| 31 Mar 17 | 1,538 | 106 | 503 | 0 |
| 31 Dec 16 | 1,468 | 94 | 460 | 0 |
| 30 Sep 16 | 1,376 | 74 | 433 | 0 |
| 30 Jun 16 | 1,344 | 79 | 349 | 0 |
| 31 Mar 16 | 1,247 | 64 | 382 | 0 |
| 31 Dec 15 | 1,202 | 63 | 486 | 0 |
| 30 Sep 15 | 1,157 | 59 | 475 | 0 |
| 30 Jun 15 | 1,068 | 45 | 316 | 0 |
| 31 Mar 15 | 1,073 | 51 | 343 | 0 |
| 31 Dec 14 | 1,082 | 52 | 477 | 0 |
| 30 Sep 14 | 1,140 | 85 | 466 | 0 |
| 30 Jun 14 | 1,195 | 114 | 455 | 0 |
| 31 Mar 14 | 1,183 | 132 | 443 | 0 |
| 31 Dec 13 | 1,175 | 130 | 395 | 0 |
Qualität der Erträge: VIMTALABS hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: VIMTALABSDie aktuellen Gewinnspannen (14.6%) sind höher als im letzten Jahr (13.1%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: VIMTALABSIn den letzten 5 Jahren sind die Einnahmen von 27.2% pro Jahr erheblich gestiegen.
Beschleunigtes Wachstum: VIMTALABSDas Gewinnwachstum des Unternehmens im letzten Jahr (19%) liegt unter seinem 5-Jahres-Durchschnitt (27.2% pro Jahr).
Erträge im Vergleich zur Industrie: VIMTALABS Das Gewinnwachstum im vergangenen Jahr (19%) übertraf nicht die Entwicklung der Branche Life Sciences 37.9% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: VIMTALABSDie Eigenkapitalrendite des Unternehmens (14.4%) wird als niedrig angesehen.